• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Hybridon Announces Two Presentations at the American College of Allergy, Asthma, & Immunology Annual Meeting

Posted on: Monday, 15 November 2004, 09:00 CST

CAMBRIDGE, Mass., Nov. 15 /PRNewswire-FirstCall/ -- Hybridon, Inc. announced today two oral presentations scheduled for November 15, 2004 at the American College of Allergy, Asthma, & Immunology meeting in Boston, Massachusetts. The first presentation, entitled "Systemic and local immune responses of second-generation immunomodulatory oligonucleotides administered to OVA-sensitized and challenged mice through different routes" (Abstract #43), will be made in Session B (Immunotherapy/Immunizations/Other) by Ekambar Kandimalla, Ph.D., Senior Director of Research at Hybridon.

The second presentation, entitled "Second-generation immunomodulatory oligonucleotides induce potent Th1 immune responses and decrease OVA-induced allergic airway inflammation and airway hyperresponsiveness in mouse model of established asthma" (Abstract # 66), will be made in Session E (Asthma and Other Lower Airway Disorders II) by Devendra Agrawal, Ph.D., Professor of Biomedical Sciences, Medical Microbiology, and Immunology and Medicine at Creighton University School of Medicine. Data included in this presentation of Hybridon's compounds have been generated under a research contract with Creighton University School of Medicine.

"In the preclinical models described in the presentations, Hybridon's IMO DNA consistently activated immune cells, which produce certain specific cytokines that are key to regulating Th1-type and Th2-type immune responses," stated Tim Sullivan, Ph.D., Vice President of Development Programs at Hybridon. "The suppression of Th2 type immune responses and promotion of Th1 type immune responses is critical to the treatment of severe allergy and asthma conditions. We have shown that, in mouse models, oral administration of second generation IMO compounds can effectively suppress allergic responses in the lung."

About Hybridon

Hybridon, Inc. is a leader in the discovery and development of novel therapeutics based on synthetic DNA. The Company's focus is to develop therapeutics independently and with partners based on two proprietary technology platforms: i) Synthetic immunomodulatory oligonucleotide (IMOTM) motifs that act to modulate responses of the immune system; and ii) Antisense technology that uses synthetic DNA to block the production of disease-causing proteins at the cellular level. Licensees of Hybridon's technology include Isis Pharmaceuticals, Inc., MethylGene, Inc., Aegera Therapeutics, Inc., Migenix, Inc., Epigenesis Pharmaceuticals, Inc., and The Immune Response Corporation.

The Company is conducting Phase 1 and Phase 2 clinical trials in oncology patients with HYB2055 (IMOxine(TM)), a 2nd-generation IMO, and a Phase 1 trial with GEM(R)231 (a 2nd-generation antisense oligonucleotide targeted to protein kinase A) in combination with irinotecan. Hybridon also is collaborating on development of additional second-generation antisense oligonucleotides for the treatment of cancer and viral infections, and has completed a Phase 1 trial of HYB2055 in healthy volunteers. Hybridon has licensed to The Immune Response Corporation Amplivax(TM) (an adjuvant application of HYB2055) as an adjuvant for IR103, a potential therapeutic and prophylactic vaccine for HIV infection being developed by The Immune Response Corporation.

This press release contains forward-looking statements concerning Hybridon that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, "believes,""anticipates,""plans,""expects,""estimates,""intends,""should,""could,""will,""may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Hybridon's actual results to differ materially from those indicated by such forward-looking statements, including risks as to whether results obtained in preclinical studies, such as those reported here, or early clinical trials will be indicative of results obtained in future preclinical studies or clinical trials, or warrant further clinical trials and product development; whether products based on Hybridon's technology will advance through the clinical trial process and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if such products receive approval, they will be successfully distributed and marketed; whether the patents and patent applications owned or licensed by Hybridon will protect the Company's technology and prevent others from infringing it; whether Hybridon's cash resources will be sufficient to fund product development; and such other important factors as are set forth under the caption "Risk Factors" in Hybridon's Quarterly Report on Form 10-Q filed on November 12, 2004, which important factors are incorporated herein by reference. Hybridon disclaims any intention or obligation to update any forward-looking statements.

Contacts:

Hybridon, Inc. Euro RSCG Life NRP

617-679-5500, x5526 212-845-4268

Tim Sullivan Robert Stanislaro (media)

E-mail: tsullivan@hybridon.com 212-845-4269

Brian Ritchie (investors)

Hybridon, Inc.

CONTACT: Tim Sullivan of Hybridon, Inc., +1-617-679-5500, ext. 5526,tsullivan@hybridon.com; or Robert Stanislaro (media), +1-212-845-4268, orBrian Ritchie (investors), +1-212-845-4269, both of Euro RSCG Life NRP

Source: PRNewswire-FirstCall

More News in this Category